lacosamide / Generic mfg.  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

21 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lacosamide / Generic mfg.
ACTRN12622001121752: Lacosamide pharmacokinetics changes in blood and breast mild during and after pregnancy

Recruiting
N/A
30
 
Melbourne Health trading as The Royal Melbourne Hospital, UCB BIOPHARMA SRL
Epilepsy
 
 
NCT01390909: Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database

Completed
N/A
12386
US
Anti-epileptic drug (AED), Mysoline® is a registered trademark of Valeant Pharmaceuticals, Neurotin® is registered trademark of Pfizer, Inc, Vimpat® is a registered trademark of UCB Pharma, Tegretol® is a registered trademark of Novartis Pharmaceuticals, Trileptal® is a registered trademark of Novartis Pharmaceuticals, Sabril® is a registered trademark of Lundbeck Inc, Felbatol® is a registered trademark of MedPointe, Topamax® is a registered trademark of Ortho-McNeill-Janssen Pharmaceuticals, Depakote® is a registered trademark of Abbott Laboratories, Zonegran® is a registered trademark of Dainippon Pharmaceutical C. Ltd., Gabatril® is a registered trademark of Cephalon, Keppra® is registered trademark of UCB Pharma, Zarontin® is a registered trademark of Pfizer, Lamictal® is a registered trademark of GlaxoSmithKline, Luminal® is a registered trademark of Abbott Laboratories, Dilantin® is a registered trademark of Pfizer, Lyrica is registered trademark of Pfizer
GlaxoSmithKline
Epilepsy
01/11
01/11
NCT01587339: Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Completed
N/A
6498
Europe
retigabine/ezogabine, Trobalt (R); Potiga (R), lacosamide, Vimpat, zonisamide, Zonegran, pregabalin, Lyrica, eslicarbazepine, Zebinix
GlaxoSmithKline
Epilepsy
03/11
07/11
PASS, NCT00771927: Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures

Completed
N/A
1005
Europe
Lacosamide, Vimpat®
UCB Pharma
Epilepsies, Partial
03/12
03/12
NCT01236001: Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Completed
N/A
192
Europe
Lacosamide, VIMPAT®
UCB Pharma
Seizures
03/12
03/12
NCT01110187: A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide

Terminated
N/A
11
US
lacosamide, Vimpat, Fosphenytoin, Dilantin
University of Alabama at Birmingham, UCB Pharma
Traumatic Brain Injury
05/12
05/12
NCT01382017: Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study

Completed
N/A
18
Europe
Lacosamide, Placebo, Carbamazepine
University of Kiel, UCB Pharma
Healthy Male Volunteers
08/12
08/12
NCT01858870: Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication

Completed
N/A
860
Europe
lacosamide, Vimpat 50mg; 100mg; 150mg; 200mg
Instituto de Investigacion Sanitaria La Fe
Epilepsy
12/12
12/12
VITOBA, NCT01098162: Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

Completed
N/A
576
Europe
UCB Pharma GmbH
Epilepsies, Partial
07/13
07/13
NCT01620840: Lacosamid-i.v.-Register

Completed
N/A
130
Europe
Lacosamide 10mg/ml, VimpatⓇ
University Hospital Schleswig-Holstein
Epilepsy With Partial Onset Seizures With or Without Secondary Generalization
11/13
11/13
NCT01399528: A Pharmacogenomic Exploration of Lacosamide Response

Unknown status
N/A
660
Europe, US
Royal College of Surgeons, Ireland, St. James's Hospital, Ireland, University College, London, Erasme University Hospital, Duke University
Epilepsy
03/14
03/14
NCT01296880: Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy

Completed
N/A
60
US
State University of New York - Downstate Medical Center, UCB Pharma
Epilepsy
07/14
07/14
VICTOS, NCT01673282: Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

Completed
N/A
315
Europe
Lacosamide, Vimpat, LCM
UCB Pharma GmbH
Focal Epilepsy With and Without Secondary Generalization
07/15
07/15
NCT01432171: Lacosamide in Preventing Seizures in Participants With Malignant Glioma

Terminated
N/A
37
US
Lacosamide, ADD 234037, Erlosamide, Harkoseride, SPM 927, Vimpat, Placebo, placebo therapy, PLCB, sham therapy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Glioma
06/17
06/17
VIBES, NCT02276053: Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors

Completed
N/A
93
Europe
UCB BIOSCIENCES GmbH, PRA Health Sciences
Brain Tumor Related Epilepsy (BTRE)
12/17
12/17
NCT03559673: Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

No Longer Available
N/A
NA
Lacosamide, Vimpat
UCB Biopharma S.P.R.L.
Epilepsies, Partial
 
 
PADRE, NCT03632915: Pharmacokinetics of Antiepileptics in Patients on CRRT

Completed
N/A
18
US
Levetiracetam, Lacosamide, Phenytoin, Phenobarbital, Ketamine, Valproic Acid
University of Maryland, Baltimore
Acute Kidney Injury, Renal Insufficiency, Renal Failure, Pharmacokinetics
12/19
12/19
SUPER-CAT, NCT05756621: Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest

Recruiting
N/A
80
Europe
Ketamine, Perampanel, Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel, Levetiracetam, Valproate, Phenytoin, Lacosamide, Topiramate, Propofol, Midazolam, Thiopental
University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliera Universitaria Integrata Verona, Ospedale Centrale Bolzano, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Azienda Ospedaliero-Universitaria Careggi, Azienda Ospedaliero-Universitaria di Parma, Santa Chiara Hospital, Ospedale M. Bufalini Cesena, Azienda Ospedaliera Brotzu, Istituto Di Ricerche Farmacologiche Mario Negri
Status Epilepticus, Cardiac Arrest
06/24
09/24
NCT05543122: Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants

Completed
N/A
39
Canada
either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe, Typical brand names include, but not limited to: Tenoretic, Wellbutrin, Zyban, Briviact, Cipralex, Lexapro, Diflucan, Vimpat, Lamictal, Keppra, Trexall, Xatmep, Ezetrol, Nexlizet
The Hospital for Sick Children, St. Justine's Hospital, University of Waterloo
Breast Feeding
12/23
03/24
NCT05422664: Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy

Enrolling by invitation
N/A
500
RoW
Lacosamide
Liu Yonghong, First Affiliated Hospital Xi'an Jiaotong University, Second Affiliated Hospital of Xi'an Jiaotong University, Xian Children's Hospital, Baoji Central Hospital, First Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Harbin Medical University, Qilu Children's Hospital of Shandong University
Autoimmune Encephalitis, Epilepsy, Seizures
05/25
12/25
EPIPOP, NCT03196466: Population Pharmacokinetics of Antiepileptic in Pediatrics

Recruiting
N/A
1000
Europe
Valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide, cannabidiol, genetic polymorphisms
Assistance Publique - Hôpitaux de Paris
Epilepsy
06/26
06/26

Download Options